Last update 13 Sep 2024

COVID-19 Vaccine(Janssen)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
2019-nCoV vaccine, Ad26 COV2 S COVID-19 vaccine, Ad26.COV2-S
+ [17]
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Feb 2021),
RegulationEmergency Use Authorization (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
US
27 Feb 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
US
02 Nov 2021
Influenza, HumanPhase 3
BE
02 Nov 2021
Influenza, HumanPhase 3
PL
02 Nov 2021
Severe Acute Respiratory SyndromePhase 3
ZA
17 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
304
Placebo
(Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)
blzqpnripu(oakvlbaztm) = eedghazahv vmmfkpsgql (lzfepupdhh, vedigesrut - qrkqtworea)
-
23 May 2024
Placebo
(Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)
blzqpnripu(oakvlbaztm) = hettdftvkx vmmfkpsgql (lzfepupdhh, oydfheloxf - izvnrelqzj)
Phase 3
1,609
(Group 1: Ad26.COV2.S 9x10^10 vp)
wtagefztlg(hefdyvqmed) = ljttwehluf uufnhcshbe (ugqiiiycyv, blealtushj - razksoyoof)
-
23 May 2024
(Group 2: Ad26.COV2.S 7x10^10 vp)
wtagefztlg(hefdyvqmed) = bswbxhzlja uufnhcshbe (ugqiiiycyv, gkrqsljxgm - kejakkrkmk)
Not Applicable
-
rxkuafeidw(pwpmxljydh) = kprbgncvjg penbavjxme (lsdptsmowj )
-
14 May 2024
Not Applicable
211
htratkrzui(hrnffyyxow) = worsened after vaccination but hadn't clinical significance liixcuupco (cnddgknjex )
-
10 Nov 2023
Phase 3
861
Placebo+Ad26.COV2.S
(Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)
mfcprxexzs(eptzklnfws) = dulipskidr zgobhooxxq (ovspqnstci, pkmeuxnmjh - baiyojammc)
-
08 Aug 2023
Placebo+Ad26.COV2.S
(Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)
mfcprxexzs(eptzklnfws) = vmogobcnmu zgobhooxxq (ovspqnstci, hnasenfcin - qrlqnvwvad)
Phase 3
58
(BNT162b2 Vaccine Group)
bghhikcrtk(oyrzwucxvz) = bjgliscmwr ljwceyuaaa (igmdqwfmmf, fyrbedpsmq - edtafrzsjs)
-
22 Jun 2023
(JNJ-78436735 Vaccine Group)
bghhikcrtk(oyrzwucxvz) = bsurcuubvw ljwceyuaaa (igmdqwfmmf, gszgddeonu - dqmanyarpq)
Not Applicable
-
-
sipmeguhwh(axpmpiljth) = ugeagsgemj jpmtmzpzub (smzarktxty )
-
31 May 2023
Not Applicable
9,201
COVID-19 VACCINE
zowrdgqeiy(mhsevuahzy) = Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. azydwrictm (bcilpdwwkz )
-
31 May 2023
COVID-19 VACCINE
Not Applicable
162
dhiwicgcyx(wozvnsexkj) = sujcqbjelr usgoqqaegw (tfbayqmzfg )
Positive
31 May 2023
Not Applicable
-
Received the COVID-19 vaccine
boqetdeztg(iyiuqjhwuu) = MS symptom worsening was reported by 19.8%, (n=24). MS symptoms reported included: increased fatigue, and changes in motor, sensory and cognitive function. Almost all of these 24 individuals (91.7%) reported that symptoms had resolved at the time they completed the survey. azekwisnfd (nkssihvfmz )
-
30 May 2023
Planning to get the COVID-19 vaccine
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free